← Back to Clinical Trials
Recruiting NCT06891911

NCT06891911 Groceries for Residents of Southeastern USA to Stop Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06891911
Status Recruiting
Phase
Sponsor Beth Israel Deaconess Medical Center
Condition Hypertension
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2025-10-14
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Dietitian-Assisted DASH groceriesSelf-directed shopping

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2025-10-14 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

GoFreshSE is a randomized control trial, testing the effects of a home-delivered, dietitian-assisted, DASH-patterned grocery intervention on blood pressure in adults with high blood pressure in Florida, Georgia, and Tennessee.

Eligibility Criteria

Inclusion Criteria: 1. Resting systolic blood pressure of 120 to \<160 mm Hg and diastolic blood pressure \<110 mm Hg 2. Resident of Florida, Georgia, and Tennessee 3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period 4. Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service 5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send/receive text messages 6. Willing and able to complete required measurement procedures 7. Able to provide consent for the study 8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study Exclusion Criteria: A. Laboratory Exclusions: 1. Serum potassium ≥5.4 mmol/L or \<3.5 mmol/L 2. Estimated glomerular filtration rate (eGFR) \<30 mL/min per 1.73 m\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 3. Hemoglobin A1c ≥6.5% B. Medication Exclusions: Unstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following: 1. GLP-1 and dual GLP-1/GIP receptor agonists 2. Anti-hypertension medications 3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors 4. Glucose lowering medications Use of any of the following medications: 1. Potassium supplement, except if part of a multivitamin 2. Warfarin (Coumadin) 3. Chronic oral corticosteroid (intermittent use is okay) 4. Weight loss medications (non-GLP-1 receptor agonists) 5. Sulfonylurea or any insulin use Any medication not compatible with participation as determined by the investigators C. Physical Exclusions: 1. Systolic blood pressure: \<120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg 2. Arm circumference \>52 cm (or the upper limit of the validated BP device) D. Medical History Exclusions: 1. Self-reported weight loss or gain of 15 pounds during prior 2 months 2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission 3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable) 4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence 5. Pregnancy or lactation or planned pregnancy during the study period 6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months 7. Hypoglycemia hospitalization in the last 12 months 8. Any other serious illness or condition not compatible with participation as determined by the investigators E. Lifestyle and Other Exclusions: 1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence 2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week 3. Active substance use disorder that would interfere with participation 4. Extreme food insecurity 5. Participation in or planning to start weight loss program 6. Current participation in another clinical trial that could interfere with the study protocol 7. Anticipated change in residence outside of eligible states prior to the end of the study 8. Families with more than 6 adults at dinner time (children count as half an adult) F. Investigator discretion

Contact & Investigator

Central Contact

Stephen P. Juraschek, MD, PhD

✉ sjurasch@bidmc.harvard.edu

📞 6177541416

Frequently Asked Questions

Who can join the NCT06891911 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06891911 currently recruiting?

Yes, NCT06891911 is actively recruiting participants. Contact the research team at sjurasch@bidmc.harvard.edu for enrollment information.

Where is the NCT06891911 trial being conducted?

This trial is being conducted at Boston, United States.

Who is sponsoring the NCT06891911 clinical trial?

NCT06891911 is sponsored by Beth Israel Deaconess Medical Center. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology